First‐in‐human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN‐101, a dual CD28/ICOS antagonist, in healthy adult subjects

• Published in: Clinical and translational science Vol. 14; no. 4; pp. 1314 - 1326
• Main Authors: Yang, Jing, Lickliter, Jason D., Hillson, Jan L., Means, Gary D., Sanderson, Russell J., Carley, Kay, Tercero, Almudena, Manjarrez, Kristi L., Wiley, Jennifer R., Peng, Stanford L.
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.07.2021; John Wiley and Sons Inc; Wiley
• Subjects: Administration, Intravenous; Adolescent; Adult; Adverse events; Aged; Antibodies; Arthritis; Autoimmune diseases; Bioavailability; CD28 antigen; CD28 Antigens - antagonists & inhibitors; CD28 Antigens - metabolism; Cytokines; Dosage; Fc receptors; Female; Flow cytometry; Fusion protein; Graft versus host disease; Healthy Volunteers; Humans; Immunization; Immunoassay; Immunogenicity; Immunoglobulins; Immunomodulation; Immunosuppressive Agents - administration & dosage; Immunosuppressive Agents - adverse effects; Immunosuppressive Agents - pharmacokinetics; Inducible T-Cell Co-Stimulator Protein - antagonists & inhibitors; Inducible T-Cell Co-Stimulator Protein - metabolism; Inflammatory bowel disease; Inflammatory diseases; Intravenous administration; Laboratories; Ligands; Lupus; Lymphocytes; Lymphocytes T; Male; Middle Aged; Pharmacodynamics; Pharmacokinetics; Staphylococcal enterotoxin B; Young Adult
• ISSN: 1752-8054; 1752-8062; 1752-8062
• DOI: 10.1111/cts.12983

ALPN‐101 (ICOSL vIgD‐Fc) is an Fc fusion protein of a human inducible T cell costimulatory ligand (ICOSL) variant immunoglobulin domain (vIgD) designed to inhibit the cluster of differentiation 28 (CD28) and inducible T cell costimulator (ICOS) pathways simultaneously. A first‐in‐human study evaluated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ALPN‐101 in healthy adult subjects. ALPN‐101 was generally well‐tolerated with no evidence of cytokine release, clinically significant immunogenicity, or severe adverse events following single subcutaneous (SC) doses up to 3 mg/kg or single intravenous (IV) doses up to 10 mg/kg or up to 4 weekly IV doses of up to 1 mg/kg. ALPN‐101 exhibited a dose‐dependent increase in exposure with an estimated terminal half‐life of 4.3–8.6 days and SC bioavailability of 60.6% at 3 mg/kg. Minimal to modest accumulation in exposure was observed with repeated IV dosing. ALPN‐101 resulted in a dose‐dependent increase in maximum target saturation and duration of high‐level target saturation. Consistent with its mechanism of action, ALPN‐101 inhibited cytokine production in whole blood stimulated by Staphylococcus aureus enterotoxin B ex vivo, as well as antibody responses to keyhole limpet hemocyanin immunization, reflecting immunomodulatory effects upon T cell and T‐dependent B cell responses, respectively. In conclusion, ALPN‐101 was well‐tolerated in healthy subjects with dose‐dependent PK and PD consistent with the known biology of the CD28 and ICOS costimulatory pathways. Further clinical development of ALPN‐101 in inflammatory and/or autoimmune diseases is therefore warranted.